Tapimmune Inc (TPIV) 0.5028 $TPIV
TapImmune Enters into Definitive Agreements to Raise $8.5 Million From the Exercise of Outstanding Warrants and in a Private Placement from New Investors
PR Newswire - Thu Aug 11, 8:00AM CDT
TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today the entry into definitive agreements to raise aggregate gross proceeds of approximately $8.5 million from an approximately $2.5 million private placement transaction with new investors and the exercise of certain outstanding warrants from existing investors that will result in gross proceeds of $6 million. The closing of the transactions are subject to customary closing conditions.
TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine
PR Newswire - Tue Jun 07, 7:00AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option agreement with Mayo Clinic and signed a worldwide license agreement to a proprietary HER2neu vaccine technology. The license gives TapImmune the right to develop and commercialize the technology in any cancer indication in which the Her2neu antigen is overexpressed. This technology, developed in the laboratory of Keith Knutson, Ph.D. at Mayo Clinic, has completed Phase 1 clinical trials in HER2neu breast cancer patients.
TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016
PR Newswire - Mon Jun 06, 8:00AM CDT
TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the LD Micro Invitational on Tuesday, June 7 at 9:00am. Dr. John N. Bonfiglio, a TapImmune Board member and Strategic Advisor, will be giving the presentation and meeting with investors.
SeeThruEquity Issues Company Update on TapImmune Highlighting New Phase 2 Clinical Study with AstraZeneca to Begin at Memorial Sloan Kettering
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
AZN: 33.56 (-0.01)
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.90 (+0.23)
TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City
PR Newswire - Fri May 27, 10:43AM CDT
TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at two financial conferences in New York City during the week of May 30 through June 3, 2016. The Company presentations will be made by Dr. John N. Bonfiglio, a TapImmune Board member and Strategic Advisor. Dr. Bonfiglio and the Company's Chairman and CEO, Dr. Glynn Wilson will be available for one-on-one meetings with investors.
Emerging Growth in Graphene 3D Printing Strong Growth Begins - Stocks Trending Now
ACCESSWIRE - Wed May 04, 7:02AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / EmergingGrowth.com - Graphene 3D Lab, Inc. (OTCQB: GPHBF) reports triple digit increase in revenue over its previous quarter.
TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
PR Newswire - Thu Apr 28, 7:30AM CDT
TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 3rd Annual Growth Capital Expo to be held on May 3rd - 5th, 2016 at Caesars Palace in Las Vegas, Nevada.
AstraZeneca Beefs Up Immuno-Oncology Pipeline with TapImmune Technology
ACCESSWIRE - Tue Apr 26, 8:03AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / AstraZeneca (AZN), a big pharma leader in immuno-oncology has placed its bets on a cancer vaccine technology from TapImmune (OTCQB: TPIV). Amongst a bevy of partnerships, collaborations, and M&A activity between big pharma and innovative biotechs focused on immunotherapies that treat cancer, TapImmune is getting much deserved attention from its bigger brethren looking to fill their pipelines with the most promising cancer cures.
TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
PR Newswire - Thu Apr 21, 8:15AM CDT
-- Study to commence Q2 2016 at Sloan Kettering Institute
AZN: 33.56 (-0.01)
Pre-Market Alert - 4 Stocks High On Our Watchlist Today
ACCESSWIRE - Fri Apr 08, 7:20AM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. SUNE, CLRB, TPIV and SKYS are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
CLRB: 2.49 (+0.01), SKYS: 3.01 (-0.03), SUNE: 0.34 (unch)
TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
PR Newswire - Thu Apr 07, 7:30AM CDT
-- Doses for use at Mayo Clinic and other clinical sites
StockNewsNow.com Publishes New SNNLive Video Interview With TapImmune, Inc.
Marketwired - Thu Mar 17, 7:31AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Glynn Wilson, Ph.D., Chairman & CEO of TapImmune, Inc. (OTCQB: TPIV), an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, according to the Company's website (see here: www.TapImmune.com). The video interview was recorded on Monday, February 11th, 2016, at the Source Capital 2016 Disruptive Growth & Healthcare Conference in New York City, NY.
TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016
PR Newswire - Mon Mar 14, 7:58AM CDT
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today the company's Director, Dr. John Bonfiglio will present at the 28th Annual ROTH Conference on March 16, 2016 at 11.30 AM PT in Salon 5. The presentation will provide an update on clinical programs and pipeline development. TapImmune management will be available for one-on-one meetings at the conference.
TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care
PR Newswire - Wed Feb 10, 7:30AM CST
Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016
TapImmune Tackles Ovarian Cancer in Fast Track Phase II Clinical Trials
ACCESSWIRE - Tue Feb 09, 8:00AM CST
Fast Track Label and Orphan Drug Designation granted for Ovarian cancer indication following positive data; Phase II trials in TPIV 200 with a partner brings TapImmune closer to a $111.9 billion cancer drug market
CERU: 1.15 (-0.05), MRK: 63.36 (-0.27), NVGN: 2.01 (+0.02), ATRA: 22.33 (-0.40), BMY: 59.29 (+0.61)
TapImmune, Inc. (OTCQB: TPIV) FDA Grants Fast Track Designation for TPIV 200
ACCESSWIRE - Tue Feb 09, 7:51AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / TapImmune, Inc. (OTCQB: TPIV) shares have been steady over the past few months as the company continues to garner FDA support for its drug candidate TPIV 200 for the treatment of ovarian cancer.
TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
PR Newswire - Wed Feb 03, 7:30AM CST
-- Expedites TapImmune's clinical development program for ovarian cancer
TapImmune Appoints Frederick G. Wasserman to its Board of Directors
PR Newswire - Wed Jan 27, 7:30AM CST
TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director.
TapImmune Enters into Definitive Agreements to Raise $8.5 Million From the Exercise of Outstanding Warrants and in a Private Placement from New Investors
PR Newswire - Thu Aug 11, 8:00AM CDT
TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today the entry into definitive agreements to raise aggregate gross proceeds of approximately $8.5 million from an approximately $2.5 million private placement transaction with new investors and the exercise of certain outstanding warrants from existing investors that will result in gross proceeds of $6 million. The closing of the transactions are subject to customary closing conditions.
TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine
PR Newswire - Tue Jun 07, 7:00AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option agreement with Mayo Clinic and signed a worldwide license agreement to a proprietary HER2neu vaccine technology. The license gives TapImmune the right to develop and commercialize the technology in any cancer indication in which the Her2neu antigen is overexpressed. This technology, developed in the laboratory of Keith Knutson, Ph.D. at Mayo Clinic, has completed Phase 1 clinical trials in HER2neu breast cancer patients.
TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016
PR Newswire - Mon Jun 06, 8:00AM CDT
TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the LD Micro Invitational on Tuesday, June 7 at 9:00am. Dr. John N. Bonfiglio, a TapImmune Board member and Strategic Advisor, will be giving the presentation and meeting with investors.
SeeThruEquity Issues Company Update on TapImmune Highlighting New Phase 2 Clinical Study with AstraZeneca to Begin at Memorial Sloan Kettering
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
AZN: 33.56 (-0.01)
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.90 (+0.23)
TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City
PR Newswire - Fri May 27, 10:43AM CDT
TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at two financial conferences in New York City during the week of May 30 through June 3, 2016. The Company presentations will be made by Dr. John N. Bonfiglio, a TapImmune Board member and Strategic Advisor. Dr. Bonfiglio and the Company's Chairman and CEO, Dr. Glynn Wilson will be available for one-on-one meetings with investors.
Emerging Growth in Graphene 3D Printing Strong Growth Begins - Stocks Trending Now
ACCESSWIRE - Wed May 04, 7:02AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / EmergingGrowth.com - Graphene 3D Lab, Inc. (OTCQB: GPHBF) reports triple digit increase in revenue over its previous quarter.
TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
PR Newswire - Thu Apr 28, 7:30AM CDT
TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 3rd Annual Growth Capital Expo to be held on May 3rd - 5th, 2016 at Caesars Palace in Las Vegas, Nevada.
AstraZeneca Beefs Up Immuno-Oncology Pipeline with TapImmune Technology
ACCESSWIRE - Tue Apr 26, 8:03AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / AstraZeneca (AZN), a big pharma leader in immuno-oncology has placed its bets on a cancer vaccine technology from TapImmune (OTCQB: TPIV). Amongst a bevy of partnerships, collaborations, and M&A activity between big pharma and innovative biotechs focused on immunotherapies that treat cancer, TapImmune is getting much deserved attention from its bigger brethren looking to fill their pipelines with the most promising cancer cures.
TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
PR Newswire - Thu Apr 21, 8:15AM CDT
-- Study to commence Q2 2016 at Sloan Kettering Institute
AZN: 33.56 (-0.01)
Pre-Market Alert - 4 Stocks High On Our Watchlist Today
ACCESSWIRE - Fri Apr 08, 7:20AM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. SUNE, CLRB, TPIV and SKYS are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
CLRB: 2.49 (+0.01), SKYS: 3.01 (-0.03), SUNE: 0.34 (unch)
TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
PR Newswire - Thu Apr 07, 7:30AM CDT
-- Doses for use at Mayo Clinic and other clinical sites
StockNewsNow.com Publishes New SNNLive Video Interview With TapImmune, Inc.
Marketwired - Thu Mar 17, 7:31AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Glynn Wilson, Ph.D., Chairman & CEO of TapImmune, Inc. (OTCQB: TPIV), an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, according to the Company's website (see here: www.TapImmune.com). The video interview was recorded on Monday, February 11th, 2016, at the Source Capital 2016 Disruptive Growth & Healthcare Conference in New York City, NY.
TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016
PR Newswire - Mon Mar 14, 7:58AM CDT
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today the company's Director, Dr. John Bonfiglio will present at the 28th Annual ROTH Conference on March 16, 2016 at 11.30 AM PT in Salon 5. The presentation will provide an update on clinical programs and pipeline development. TapImmune management will be available for one-on-one meetings at the conference.
TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care
PR Newswire - Wed Feb 10, 7:30AM CST
Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016
TapImmune Tackles Ovarian Cancer in Fast Track Phase II Clinical Trials
ACCESSWIRE - Tue Feb 09, 8:00AM CST
Fast Track Label and Orphan Drug Designation granted for Ovarian cancer indication following positive data; Phase II trials in TPIV 200 with a partner brings TapImmune closer to a $111.9 billion cancer drug market
CERU: 1.15 (-0.05), MRK: 63.36 (-0.27), NVGN: 2.01 (+0.02), ATRA: 22.33 (-0.40), BMY: 59.29 (+0.61)
TapImmune, Inc. (OTCQB: TPIV) FDA Grants Fast Track Designation for TPIV 200
ACCESSWIRE - Tue Feb 09, 7:51AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / TapImmune, Inc. (OTCQB: TPIV) shares have been steady over the past few months as the company continues to garner FDA support for its drug candidate TPIV 200 for the treatment of ovarian cancer.
TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
PR Newswire - Wed Feb 03, 7:30AM CST
-- Expedites TapImmune's clinical development program for ovarian cancer
TapImmune Appoints Frederick G. Wasserman to its Board of Directors
PR Newswire - Wed Jan 27, 7:30AM CST
TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director.
